A data gap can look simple on a requirements list: information is expected and the file does not contain it. But the strategic question begins one level deeper. What regulatory uncertainty is that information meant to resolve—and is that uncertainty already addressed by other evidence?
That distinction matters because more testing is not automatically more informative. The strongest path is the one that answers the scientific question proportionately and transparently.
The real issue is relevance, not completeness
A thoughtful gap assessment does more than mark studies present or absent. It asks what each information requirement contributes to the assessment, whether the evidence is applicable to the product under review, and whether another line of evidence already addresses the same uncertainty.
This is where regulatory science becomes more valuable than checklist completion. A nominal gap and a meaningful evidence gap are not always the same thing.
“A waiver is not an argument that new data would be inconvenient. It is an argument that additional testing would not materially improve the regulatory conclusion.”
What makes a waiver credible
A defensible rationale has a clear scientific through-line. The evidence must be relevant to the specific question, its applicability must be explained, and uncertainty cannot be hidden behind a generic statement.
The most persuasive position is usually the one that makes the evaluator's decision easier: the issue is defined, the supporting evidence is coherent, and the limits of the argument are acknowledged.
Where companies lose time
The expensive version of this decision happens late—after a dossier has been assembled, when a gap becomes visible as a submission problem. Another common mistake is assuming that a rationale accepted in one jurisdiction will carry the same weight in a different product and regulatory context.
Early review creates room to choose deliberately: generate data where the uncertainty genuinely needs it, or build the scientific case where the existing evidence can do the work.
The strategic decision
The useful question is not “Can we request a waiver?” It is “What evidence would let a reviewer reach a confident conclusion, and what is the most defensible way to provide it?”
That answer is specific to the product, endpoint, evidence base and registration objective. Getting it right early can prevent both unnecessary studies and under-supported arguments.
This article provides general regulatory perspective and is not advice on a specific submission.